Daehan Nupharm Overview

  • Year Founded
  • 1984

Year Founded

  • Status
  • Public

  • Employees
  • 381

Employees

  • Stock Symbol
  • 054670

Stock Symbol

  • Investments
  • 3

  • Share Price
  • $3.77
  • (As of Friday Closing)

Daehan Nupharm General Information

Description

Daehan Nupharm Co Ltd is a South Korea-based company operating in the pharmaceutical sector. It is engaged in producing pharmaceutical products, animal health and nutrition, and bioproducts.

Contact Information

Website
www.dhnp.co.kr
Formerly Known As
Dae Han Shinyak Company
Ownership Status
Publicly Held
Financing Status
Corporation
Corporate Office
  • 66 Jeyakgongdan 1-gil Hyangnameup
  • Gyeonggi
  • Hwaseong, 18622
  • South Korea
+82
Primary Industry
Pharmaceuticals
Stock Exchange
KRX
Corporate Office
  • 66 Jeyakgongdan 1-gil Hyangnameup
  • Gyeonggi
  • Hwaseong, 18622
  • South Korea
+82

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Daehan Nupharm Stock Performance

As of 13-Nov-2026, Daehan Nupharm’s stock price is $3.77. Its current market cap is $52.9M with 14M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$3.77 $3.77 $3.26 - $5.43 $52.9M 14M 13.9K $1.17

Daehan Nupharm Financials Summary

As of 30-Jun-2026, Daehan Nupharm has a trailing 12-month revenue of $146M.

In Thousands,
USD 		TTM 30-Jun-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 97,094 108,324 77,778 97,063
Revenue 145,724 142,222 148,183 156,199
EBITDA 22,190 14,598 17,524 19,551
Net Income 16,491 10,721 11,337 9,593
Total Assets 182,240 188,321 150,231 137,293
Total Debt 68,988 68,719 40,345 28,399
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Daehan Nupharm Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Daehan Nupharm‘s full profile, request access.

Request a free trial

Daehan Nupharm Patents

  • 15

    Total Documents Applications and Grants

  • Total Patents Families

  • Granted

  • 2

    Pending

  • Expiring in next 12 mo

Daehan Nupharm Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2025239464-A1 Novel peptide and antiviral use thereof Pending 14-May-2024
WO-2024214905-A1 Antibody-peptide fusion protein Inactive 12-Apr-2023
EP-4621409-A1 Novel antiviral peptide Pending 16-Nov-2022
WO-2024106940-A1 Novel antiviral peptide Inactive 16-Nov-2022
WO-2024054009-A1 Novel antiviral peptide Inactive 08-Sep-2022
To view Daehan Nupharm’s complete patent history, request access »

Daehan Nupharm Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Daehan Nupharm Investments & Acquisitions (3)

Daehan Nupharm’s most recent deal was a Corporate with Baverstock for . The deal was made on 22-Sep-2015.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Baverstock 22-Sep-2015 Corporate Energy Exploration
Galaz Energy 22-Feb-2010 Secondary Transaction - Private Holding Companies
Baverstock 03-Mar-2008 Merger/Acquisition Energy Exploration
To view Daehan Nupharm’s complete investments and acquisitions history, request access »

Ready to get started?

Request a free trial

Daehan Nupharm ESG

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

Rank

Percentile

Pharmaceuticals

Industry

Rank

Percentile

Pharmaceuticals

Subindustry

Rank

Percentile

To view Daehan Nupharm’s complete esg history, request access »

Daehan Nupharm Exits (3)

Daehan Nupharm’s most recent exit was on 22-Sep-2015 from Baverstock. The exit was categorized as .

Company Name Exit Date Exit Type Exit Size Status Buyers
Baverstock 22-Sep-2015 Completed
Galaz Energy 22-Feb-2010 Completed
Baverstock 03-Mar-2008 Merger/Acquisition Completed
  • 2 buyers
To view Daehan Nupharm’s complete exits history, request access »

Daehan Nupharm FAQs

  • When was Daehan Nupharm founded?

    Daehan Nupharm was founded in 1984.

  • Where is Daehan Nupharm headquartered?

    Daehan Nupharm is headquartered in Hwaseong, South Korea.

  • What is the size of Daehan Nupharm?

    Daehan Nupharm has 381 total employees.

  • What industry is Daehan Nupharm in?

    Daehan Nupharm’s primary industry is Pharmaceuticals.

  • Is Daehan Nupharm a private or public company?

    Daehan Nupharm is a Public company.

  • What is Daehan Nupharm’s stock symbol?

    The ticker symbol for Daehan Nupharm is 054670.

  • What is the current stock price of Daehan Nupharm?

    As of 13-Nov-2026 the stock price of Daehan Nupharm is $3.77.

  • What is the current market cap of Daehan Nupharm?

    The current market capitalization of Daehan Nupharm is $52.9M.

  • What is Daehan Nupharm’s current revenue?

    The trailing twelve month revenue for Daehan Nupharm is $146M.

  • What is Daehan Nupharm’s annual earnings per share (EPS)?

    Daehan Nupharm’s EPS for 12 months was $1.17.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process